HT
ZNTL icon

Headlands Technologies’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Headlands Technologies’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,899
Closed -$70K – 1045
2026
Q1 		$70K Buy
+29,899
New +$77.2K 0.01% 682

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Headlands Technologies's ZNTL Position: Q2 2026 in Review

Headlands Technologies sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 29,899 shares — an estimated $70K sold.

Headlands Technologies first reported a position in ZNTL in Q1 2026 and held it in 1 quarter. The position peaked at $70K in Q1 2026. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Headlands Technologies reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 29,899 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $70K.
  • Headlands Technologies first reported a position in Zentalis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Headlands Technologies's Zentalis Pharmaceuticals position peaked at $70K in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.